 Connection
Paul Bunn to Melanoma
This is a "connection" page, showing publications Paul Bunn has written about Melanoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.399 |
|
|
|
-
Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25.
Score: 0.203
-
Lin EP, Hsu CY, Berry L, Bunn P, Shyr Y. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses. JAMA Netw Open. 2022 08 01; 5(8):e2227211.
Score: 0.130
-
Lindmo T, Boven E, Mitchell JB, Morstyn G, Bunn PA. Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody. Cancer Res. 1985 Oct; 45(10):5080-7.
Score: 0.041
-
Gonzalez R, Salem P, Bunn PA, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol Biother. 1991 Dec; 3(4):192-6.
Score: 0.016
-
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 03; 72(1):77-89.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|